A Phase 2 interventional study of Melatonin group and Placebo group in Bone Loss, sponsored by Cairo University. Not yet recruiting. Open to participants aged 18 Years to 30 Years. Per ClinicalTrials.gov, last updated 2026-11-06.
Sponsored by Cairo University · Phase 2, Interventional, and Treatment
This study will be conducted at the Department of Oral and Maxillofacial Surgery, Faculty of Dentistry, Cairo University. It will include patients aged 18-30 years presenting with non-restorable mandibular molars indicated for extraction and delayed implant placement.
Eligible patients will be randomly allocated into two equal groups:
Postoperative care will include standardized medications and oral hygiene instructions. Patients will be followed up clinically and radiographically. CBCT will be used to assess the primary outcome, which is the dimensional change in vertical alveolar bone height (ΔH). At 12 weeks, core biopsy specimens will be obtained for histopathological assessment of bone quality, including newly formed bone, bone maturation, trabecular architecture, and osteoblastic activity.
Sample size: The total sample size will be determined based on the primary outcome (ΔH), using an appropriate statistical power calculation, with equal allocation between the two groups. The final number of participants will be specified according to the statistician's sample size calculation.
661 studies on the registry are indexed under Bone Diseases, Metabolic; 93 are open to participants now.
This study's planned enrollment of 40 is below the median of 60 across 509 interventional studies indexed under Bone Diseases, Metabolic.
Browse Bone Diseases, Metabolic studies →Cairo University is the lead sponsor of 4,941 studies on the registry; 1,458 are open to participants now.
Of its 37 completed or terminated interventional studies of FDA-regulated products, 5 (14%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Melatonin group
Drug: Placebo group
Eligible patients will undergo atraumatic extraction of non-restorable mandibular molars under local anesthesia, followed by socket curettage and irrigation with sterile 0.9% saline. The extraction socket will be filled with locally applied melatonin gel. A collagen membrane will then be adapted to cover the socket, followed by primary wound closure using interrupted sutures. All participants will receive standardized postoperative medications and oral hygiene instructions. Clinical follow-up will be conducted at 3 days and 1 week postoperatively. At 12 weeks, CBCT examination will be performed to assess changes in vertical alveolar bone height (ΔH), followed by core biopsy for histopathological evaluation of bone qualit
Eligible patients will undergo atraumatic extraction of non-restorable mandibular molars under local anesthesia, followed by socket curettage and irrigation with sterile 0.9% saline. The extraction socket will be filled with locally applied placebo gel. A collagen membrane will then be adapted to cover the socket, followed by primary wound closure using interrupted sutures. All participants will receive standardized postoperative medications and oral hygiene instructions. Clinical follow-up will be conducted at 3 days and 1 week postoperatively. At 12 weeks, CBCT examination will be performed to assess changes in vertical alveolar bone height (ΔH), followed by core biopsy for histopathological evaluation of bone quality.
the dimensional change in vertical alveolar bone height
radiographically by cone beam C.T
Time frame: 12 weeks
No study locations are listed for this record.
Start is estimated for Nov 2026; primary completion for Oct 2027, 11 months later.
Of 19 phase 2 interventional studies under Bone Diseases, Metabolic, half reached primary completion within 31 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 34. This study's planned 11 months is below that.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Melatonin